A series of developments in August highlight technological advances, persistent access issues, and policy debates shaping the future of women’s reproductive health, from remote pregnancy monitoring to surgical cancer risk reduction and vaccine policy controversies.
August brought a concentrated run of developments in women’s health, ranging from access issues in maternity care to new guidance on ovarian cancer prevention and a fresh round of debate over childhood vaccines. Contemporary OB/GYN’s monthly roundup captured how clinical research, policy and specialist practice continue to collide in ways that affect patients across the reproductive lifespan.
One of the clearest themes was access. A study published in the American Journal of Obstetrics & Gynecology Maternal-Fetal Medicine found that patient-operated remote ultrasonography can be used to complete biophysical profiles in high-risk pregnancies with the Pulsenmore ES system. The findings suggest a practical way to extend antenatal surveillance to people who live far from specialist care or struggle with transport, an issue that remains particularly pressing in maternity care deserts.
That access problem was reinforced by March of Dimes, which said 34.6% of US counties are still classified as maternity care deserts, affecting about 2.4 million women of reproductive age. The report said the figure has not improved since 2016, underscoring how persistent gaps in local obstetric services continue to shape pregnancy care.
Clinical practice also saw fresh attention. Contemporary OB/GYN published an in-depth review on urinalysis for obstetricians and gynaecologists, pushing beyond routine screening to cover findings that can matter in pregnancy, kidney disease and liver disease. The review highlighted when dipstick testing is not enough, how to think about proteinuria and haematuria, and which results should prompt referral to nephrology, urology, hepatology or maternal-fetal medicine.
Another major update came from the American College of Obstetricians and Gynecologists, which strengthened its advice on bilateral salpingectomy at the time of hysterectomy and other abdominopelvic surgery. ACOG says removing both fallopian tubes can meaningfully lower lifetime ovarian cancer risk and should be considered the preferred option for permanent contraception. The organisation also encourages broader use of the procedure when other abdominal surgery creates an opportunity to offer cancer prevention.
The month was not limited to surgical prevention. AbCellera reported positive phase 2 top-line data for ABCL635, an investigational antibody targeting NK3R for moderate-to-severe menopausal vasomotor symptoms. The company said the drug lowered both the frequency and severity of hot flashes and improved sleep, while one specialist quoted in the announcement said the findings could point to a more convenient option if later trials confirm the results.
Policy developments added a more contentious note. After President Donald Trump signed an executive order titled “Gold Standard Childhood Vaccine Recommendations”, several medical societies, including groups focused on maternal-fetal and paediatric health, raised concerns about the potential public health consequences. Their reaction reflected a broader point echoed by the Society for Maternal-Fetal Medicine: maternal and childhood health are closely linked, and changes to immunisation policy can ripple far beyond paediatrics.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
